Participants
Eleven PD patients (PD; women n = 5, men n = 6; mean age 65.4 ± 4.5 years, body mass 72.2 ± 12.4 kg, height 168.7 ± 8.9 cm) assessed with the Hoehn and Yahr scale (H&Y)9 to be mildly affected, and 11 healthy age-matched controls (HCO; women n = 6, men n = 5; mean age 63.4 ± 4.6 years, body mass 74.1 ±18.9 kg, height 166.4 ± 8.9 cm) participated in our study (Table 1). All PD and HCO subjects were non-demented (confirmed by a neuropsychologist), right-handed, and the PD patients had an affected dominant side (Table 1). All subjects wrote informed consent prior participation in this study which was approved by the local ethical review board. All study participants underwent EEG recording, PET/CT neuroimaging and neuropsychological cognitive assessment, and PD patients underwent additional clinical neurological evaluation. All PD patients’ testing procedures were conducted during their “off-medication” phase, i.e. after an overnight 12-hours withdrawal of anti-parkinsonian drugs (24 hours for extended release medications).